Rowing Following Breast Cancer Chemotherapy

Launched by UNIVERSITY OF FLORIDA · Apr 27, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how rowing exercises can help improve heart health in women who have survived breast cancer. Many breast cancer survivors face a higher risk of heart problems due to the chemotherapy treatments they received. The study aims to see if a special rowing program can reduce this risk and promote better overall health for these survivors.

To participate in the trial, women need to be between 40 and 80 years old, have been diagnosed with early-stage breast cancer, and completed their treatment within the last 6 to 24 months. They should not currently be receiving any other cancer treatments like chemotherapy or radiation. Participants will have the opportunity to engage in a supervised rowing exercise program and receive support throughout the study. This trial not only hopes to enhance the health and well-being of its participants but also aims to gather valuable information that could benefit many breast cancer survivors in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • diagnosis of primary invasive non-metastatic breast cancer, stages I-III
• • female based on biological sex
• • 40 to 80 years of age
• • completed breast cancer treatment 6 to 24 months prior to study enrollment. Adjuvant endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy and bisphosphonates are allowed within 6 months prior to study enrollment and during study participation
• • absence of contraindications to exercise or study participation
• • study clinician approval
• Exclusion Criteria:
• • do not meet inclusion criteria
• • receiving or scheduled to receive treatment for breast cancer (i.e., chemotherapy, surgery, or radiation) during study participation is not allowed. Adjuvant endocrine therapy, CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy and bisphosphonates are allowed during study participation
• • lymphedema stage ≥ 2 prior to study enrolment
• • any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent)
• • current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)
• • consistent participation in ≥150 min/week of moderate-intensity rowing exercise training in previous 6 months